The PDF file you selected should load here if your Web browser has a PDF reader plug-in installed (for example, a recent version of Adobe Acrobat Reader).

If you would like more information about how to print, save, and work with PDFs, Highwire Press provides a helpful Frequently Asked Questions about PDFs.

Alternatively, you can download the PDF file directly to your computer, from where it can be opened using a PDF reader. To download the PDF, click the Download link above.

Fullscreen Fullscreen Off


E.C.G is the most widely used test for both the diagnosing and estimating the prognosis of CAD. ST segment and T wave changes are most commonly evaluated parameters of E.C.G. Atorvastatin have found to decrease ischemic events apart from its hypolipidemic effect. The main objective of this open prospective randomized, controlled study was to evaluate the effect of addition of atorvastatin to conventional antianginal treatment on ST segment and T wave changes on E.C.G. The study was conducted for duration of 2 months in 30 patients of CAD (15 in each group). Group A was started on conventional antianginal treatment and group B was started on Atorvastatin 20 mg once a day at night in addition to conventional treatment. The ECG changes were recorded after 15, 30, 45 and 60 days using 12 lead E.C.G. At the end of the study, no significant difference was found in E.C.G changes between the group A and group B. A slight improvement in ST segment changes in group B patients was observed but the effect was statistically not significant. So, addition of atorvastatin to conventional antianginal treatment did not have a significant effect on reversal of ischemic changes on ECG in patients of CAD.

Keywords

CAD, Atorvastatin, E.C.G, ST Segment, T Wave.
User
Notifications
Font Size